Tag: MDD
-
FDA Clears At-Home Neuromodulation Device for Major Depressive Disorder: Proliv™Rx
Overview: A new option for major depressive disorder The U.S. Food and Drug Administration (FDA) has cleared Proliv™Rx, an at-home neuromodulation device, for use as an adjunctive treatment for adults with major depressive disorder (MDD) who have not achieved satisfactory improvement after at least one previous therapy. This marks a notable milestone in the growing…
-
FDA Clears At-Home Neuromodulation Device for Major Depressive Disorder
FDA Clears At-Home Neuromodulation Device for Major Depressive Disorder The U.S. Food and Drug Administration has cleared Proliv™Rx, an at-home neuromodulation therapy, to be used as an adjunctive treatment for adults diagnosed with major depressive disorder (MDD) who have not achieved satisfactory improvement after at least one prior antidepressant. The approval marks a notable milestone…
-
New Frontiers in Treating Treatment-Resistant Depression: Vagus Nerve Stimulation and Beyond
Overview: The Rising Need for Neuromodulation in MDD Major depressive disorder (MDD) remains a global health challenge, with a significant subset of patients — up to 35% — not responding after four or more standard treatment trials. In the face of this treatment resistance, researchers and clinicians are turning to neuromodulation as a viable alternative…
-
Vagus Nerve Stimulation Offers Fresh Outlook for Treatment-Resistant Depression: Conference Report
Introduction: A Growing Challenge in Depression Care Major depressive disorder (MDD) remains a leading cause of disability worldwide. In a clinical landscape where up to 35% of patients do not respond to four or more standard treatments, researchers and clinicians are exploring innovative neuromodulation approaches. Vagus nerve stimulation (VNS) is gaining renewed attention as a…